Home Archives 2012 May

Monthly Archives: May 2012

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 15 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
COMBIVIRViiv Hlthcarelamivudine; zidovudine5,859,021May 15, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 17 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
PLAVIXSanofi Aventis Usclopidogrel bisulfate4,847,265*PEDMay 17, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
FDA Orange Book archives from 2005 to
present
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 22 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
ACTONELWarner Chilcottrisedronate sodium6,096,342*PEDMay 22, 2012
VIRAMUNEBoehringer Ingelheimnevirapine5,366,972*PEDMay 22, 2012
VIRAMUNE XRBoehringer Ingelheimnevirapine5,366,972*PEDMay 22, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

I am running a special discount at DrugPatentWatch through the end of June:

50% off all reports through June 30 2012.

These pharmaceutical industry reports are produced by data-mining the DrugPatentWatch Database, and provide detailed information on FDA-approved pharmaceutical drugs.

Please contact me with any special data needs beyond the existing report catalog.

Global Drug Patent Inventor Report
The Global Drug Patent Inventor Reportprofiles the individuals, countries, and US states leading pharmaceutical innovation.
$5,000 $2,500

more…

 

Individual Country Drug Patent Inventor Reports
These Individual Country Drug Patent Inventor Reportsprofile the individuals leading pharmaceutical innovation in 20 countries, including Australia, Belgium, Canada, China, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, United Kingdom, and United States.
$195 – $795 $97.50 – $397.50

 Drug Patent Challenge Report

Profiles the companies that successfully challenged pharmaceutical drug patents since 2000.

  • Companies with the most successful patent challenges
  • The drugs for which each firm successfully challenged a patent
  • The companies that have received FDA approval for each listed drug
    Report Highlights:

  • More than 60 companies profiled
  • More than 80 drugs profiled

$800 $400


 Orphan Drug Report

Profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity since 2000.

  • The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
  • Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
  • All FDA-listed patents covering each Orphan Drug

Report highlights:

  • More than 400 pages
  • More than 90 drugs profiled

$500 $250

See all the reports at the DrugPatentWatch Reports page.